“Why did FDA delay the approval of MDMA therapy?” interview with Rick Doblin

This is a recent quite long interview with Rick Doblin published in late December. It provides more background to the very disappointing thumbs down for approval of MDMA-assisted therapy from the US FDA last year. Intriguingly Rick speaks a fair amount about the helpful possibilities of MDMA-assisted group therapy.

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Question: "What is one psychedelics story you will be following in 2025?"

Next
Next

Brief interview with Ben Malcolm, 'Spirit Pharmacist'